Travere Therapeutics, Inc.

TVTX

$66.54

-1.03%

N/A-$0.69

Healthcare

Biotechnology

NASDAQ

Active Trading

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an ...

Fundamental Analysis of TVTX

Loading analysis...

Profitability

Net Margin-7.35%

Operating Margin-6.84%

Valuation

P/E Ratio-147.87x

Current Ratio4.05

Efficiency

ROE-55.79%

ROA-5.44%

Fundamental Analysis of TVTX

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.

Key Strengths of TVTX

Industry-leading gross margins
Strong cash flow generation
High R&D investment ratio
Market leadership in AI chips

Risk Factors of TVTX

Premium valuation multiples
Semiconductor cycle exposure
Intense competition
Geographic concentration

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$6.19B

-147.9x

P/E Ratio

10.5x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin94.41%

Net Profit Margin-7.35%

Debt/Equity Ratio25.16

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of TVTX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of TVTX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	-20.52%	—	—	Flat
Operating Margin	—	2.33%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of TVTX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	4.046	—	—	Flat
Quick Ratio	—	3.995	—	—	Flat
Debt / Equity	—	25.157	—	—	Flat

Valuation of TVTX

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-38.39x	—	—	Flat
P/B	—	216.56x	—	—	Flat

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer